184 related articles for article (PubMed ID: 17323185)
1. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Takada J; Iba K; Imoto K; Yamashita T
J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
[TBL] [Abstract][Full Text] [Related]
2. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
Iba K; Takada J; Hatakeyama N; Ozasa Y; Wada T; Yamashita T
J Orthop Sci; 2008 Sep; 13(5):438-41. PubMed ID: 18843458
[TBL] [Abstract][Full Text] [Related]
3. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
5. Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Iizuka T; Matsukawa M
Climacteric; 2008 Aug; 11(4):287-95. PubMed ID: 18645694
[TBL] [Abstract][Full Text] [Related]
6. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
7. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
[TBL] [Abstract][Full Text] [Related]
9. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Hosking D; Adami S; Felsenberg D; Andia JC; Välimäki M; Benhamou L; Reginster JY; Yacik C; Rybak-Feglin A; Petruschke RA; Zaru L; Santora AC
Curr Med Res Opin; 2003; 19(5):383-94. PubMed ID: 13678475
[TBL] [Abstract][Full Text] [Related]
10. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Giljević Z; Vlak T
Reumatizam; 2006; 53(2):66-71. PubMed ID: 17580558
[TBL] [Abstract][Full Text] [Related]
12. Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate.
Palacios S; Neyro JL; Ferrer J; Villero J; Cañada E; Redondo E; Caloto MT; Nocea G;
Menopause; 2012 Jan; 19(1):67-74. PubMed ID: 21926927
[TBL] [Abstract][Full Text] [Related]
13. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
14. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
[TBL] [Abstract][Full Text] [Related]
16. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Miller PD; Delmas PD; Lindsay R; Watts NB; Luckey M; Adachi J; Saag K; Greenspan SL; Seeman E; Boonen S; Meeves S; Lang TF; Bilezikian JP;
J Clin Endocrinol Metab; 2008 Oct; 93(10):3785-93. PubMed ID: 18682511
[TBL] [Abstract][Full Text] [Related]
17. [The effect of risedronate treatment on bone turnover markers in patients with hip fracture].
Altintaş F; Ozkut AT; Beyzadeoğlu T; Eren A; Güven M
Acta Orthop Traumatol Turc; 2007; 41(2):132-5. PubMed ID: 17483649
[TBL] [Abstract][Full Text] [Related]
18. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
[TBL] [Abstract][Full Text] [Related]
19. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
20. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
